Abstract
We designed and developed a multiwell tissue culture plate irradiation setup, and intensity modulated radiotherapy plans were generated for 96-, 24-, and 6-well tissue culture plates. We demonstrated concordance between planned and measured/imaged radiation dose profiles using radiochromic film, a 2D ion chamber array, and an electronic portal-imaging device. Cell viability, clonogenic potential, and γ-H2AX foci analyses showed no significant differences between intensity-modulated radiotherapy and open-field, homogeneous irradiations. This novel platform may help to expedite radiobiology experiments within a clinical environment and may be used for wide-ranging ex vivo radiobiology applications.
Highlights
Radiotherapy is an important cancer treatment modality as more than half of cancer patients will require some form of radiotherapy during their illness [1]
We aimed to develop and validate a high-throughput in vitro radiobiology platform using Intensity-modulated radiotherapy (IMRT) and widely available clinical radiotherapy facilities for conducting radiobiology experiments within a clinical environment and to investigate beam inhomogeneity issues when using multiwell tissue culture plates
The holder was able to be attached to the indexed immobilisation positioning system of both a clinical linear accelerator and computed tomography (CT) scanner with a base plate made of medium-density fibreboard (Figure 1B–D)
Summary
Radiotherapy is an important cancer treatment modality as more than half of cancer patients will require some form of radiotherapy during their illness [1]. Preclinical radiobiology experiments can provide valuable information about tumours and normal tissue radiation effects at the molecular level and serve as a framework to study radiation–. These preclinical explorations may assist in developing clinical trial strategies, which can improve the outcomes of radiotherapy treatments. Various approaches have been used to improve the therapeutic ratio in radiotherapy [2]. A large number of novel anticancer agents targeting cancer cell signalling pathways and several immunotherapy agents are in routine clinical use. Combining these novel agents with radiation offers many therapeutic opportunities [3]. The challenge is to suggest optimal clinical radiation–drug schedules given a large number of potential combinations, doses, and schedules of each agent
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
